The Christoph Merian Foundation is the sole landowner of Dreispitz and promotes its development by granting building rights. This development aims at transforming parts of this already attractive logistics and business plot into a modern and vibrant multi-use city district with a distinct identity. It will combine business, residential and leisure areas as well as culture and shopping. In addition to the already existing 400 businesses, the potential for nearly 6'000 new jobs will be created through concentration and densification, and in addition to that, apartments will be available for some 2'500 residents.

As regards the urban development, this transformation is led by a vision created by the renowned architects Herzog & de Meuron. Since 2009 this vision is being put into practice: For an area that comprises around a tenth of the whole of Dreispitz, the former "Zollfreilager" (where in the past goods in transit were stored duty free), there already is an authoritative development plan in place. All in all 300 residences are being created in this new area now called the "KunstFreilager". An arts college as well as various institutions and players from the arts and creative industries have already taken a front seat in this development as pioneers and trendsetters and have moved to Dreispitz. Notably two projects have been instrumental in realizing the KunstFreilager: The "Dreispitzhalle", an indoor event venue, and the art-, studio- and business complex "Oslo". But besides developing infrastructure and buildings there is also much consideration for public spaces and green areas.

Find more information at: www.dreispitz.ch
 
Contact:
Christoph Merian Stiftung
Herr Felix Leuppi
St. Alban-Vorstadt 5
Postfach
4002 Basel
Tel. +41 61 226 33 16
f.leuppianti spam bot@dreispitzanti spam bot.ch

Prof. Hans-Florian Zeilhofer, Head of cranio-maxillo-facial surgery at the the University Hospital of Basel, cofounder and board member of AOT comments: “The funding gives us the chance to create a unique system applying cutting edge technology to assist the surgeon in executing complex operations successfully. Our product will be the first to apply laser technology to cut bones and represents therefore a real technological breakthrough.” The start-up combines expertise in laser technology, imaging, navigation and robotics and builds on the intense research at the Hightech Research Center of Cranio-Maxillofacial Surgery (HFZ) at the University Hospital Basel. Medics, physicists, computer scientists, engineers, mathematicians, artists and scientists of different research fields are working there together in interdisciplinary ways.

Advanced Osteotomy Tools - AOT AG, Basel, is a privately owned MedTech company. It is a spin-off of the University Hospital Basel dedicated to the development of medical devices and tools for osteotomy pursuing the vision of “contact-free bone surgery using laser, robotics and navigation systems”. The 1st product to be developed, registered and marketed will be an innovative medical device to perform all interventions of Cranio-Maxillo-Facial (CMF) as well as several other complex surgeries of the human body.

Contact: Dr. Alfred E. Bruno, CEO address: Advanced Osteotomy Tools – AOT AG c/o BASEL INKUBATOR, Hochbergerstrasse 60C, CH-4057 Basel, Switzerland phone: +41 61 265 90 41 mobile: +41 78 716 69 59 mail: abrunoanti spam bot@aot-swissanti spam bot.ch

Ten percent target

In the last two years, EasyJet has invested around 150 million francs in the EAP, expanded its fleet from four to seven planes and, with a view to the coming summer, is including Toulouse, Faro and Ibiza among its destinations. A total of 36 destinations will be offered, so EasyJet employs 250 people locally.

The company aims to grow further in Basel. “For 2012 we are targeting a growth of eight to ten percent”, says Thomas Hagensen, General Manager of Easyjet for the regions Switzerland, Germany, Eastern Europe, Scandinavia, explaining the company’s ambitious target.

www.easyjet.com
www.euroairport.com

Leasing
Schild AG Liestal
Marc Löhle
Eichenweg 1
CH-4410 Liestal
Tel. 061 906 97 92
liegenschaftenanti spam bot@schildanti spam bot.ch

It is no coincidence that the signing takes place just before Art Basel Miami Beach kicks off this year to celebrate its 10th anniversary. The regular exchanges between the two cultural capitals go back to the first Art Basel Miami Beach in the year 2002. Since then, the two cities have continually intensified their relationship. For Basel-Stadt, today’s signing of the official partnership treaty is also a confirmation of MCH Group’s commitment to Miami Beach as a business location.

The cities’ extensive common interests in the cultural field are at the heart of the partnership arrangement. Furthermore, strategic cooperation will also be promoted in the economic, trade, education and research fields. The city partnership model represents a platform for lively exchanges between all actors interested in these areas.

Extension of the global network
Basel is already twinned with the State of Massachusetts and the city of Shanghai, China. Building on mutual strengths, city partnerships represent an integral part of the activities performed by the Department of Presidential Affairs that have both a direct and an indirect impact on the positive development of the cities involved. Similar to Basel, the southern US city of Miami Beach is also the site of numerous cultural events, ranging from exhibitions of classic collections and modern art to ballet performances and concerts.

The Art Basel Miami Beach show is one of the most prominent art events in the United States. With its additional thriving clusters in the fields or tourism, business development and education, Miami Beach is an inspiring partner city and a welcome addition to Basel’s global network. Miami Beach has entered into over ten of such partnerships, with Basel being the only partner city in the central European region.

For further information, please contact:
Sabine Horvath
Leiterin Aussenbeziehungen und Standortmarketing Basel-Stadt
Phone +41 (0)61 267 40 87
Mobile: +41 (0)79 623 30 14
E-mail: sabine.horvathanti spam bot@bsanti spam bot.ch

For detailed information go to www.react-basel.ch./en

smeyers
Immobilien ⋅ Management
Patrick Näpflin
Dornachersterasse 230
CH-4053 Basel
Tel. +41 (0)58 322 88 71
Fax +41 (0)58 322 88 90
patrick.naepflinanti spam bot@smeyersanti spam bot.ch

“This award is testimony to the pioneering nature of the BioVersys technology which represents an exciting novel approach towards achieving new anti-bacterial therapies as well as the potential to rejuvenate older, proven, safe and inexpensive antibiotics. In a world saturated with expensive medicines, this pioneering work may help address the escalating costs of healthcare in antiinfectives by making obsolete antibiotics relevant again.” said Dr. Seng Chin Mah, Chairman of the Board.

Dr. Peter Burckhardt, CEO of EVA and President of BioValley Business Angels Club BioBAC, comments: “We are proud of BioVersys. The award is an external validation of our efforts in coaching and financing of spin-offs who translate scientific results into business.”

BioVersys AG is a privately held biopharmaceuticals company. It is a spin-off company from the ETH Zurich located in Basel. The company focuses on the research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and thus restore the efficacy of existing antibiotics. (www.bioversys.com)

Swiss Technology Award Switzerland’s leading technology award presents the most innovative companies and promotes the innovate power of Switzerland. Initiated by Nicholas Hayek and Branko Weiss the award can look back on a long tradition and track record: Since 1987 over 1900 projects applied and about 370 winners were awarded. (www.swiss-innovation.com/award)

Media contact:
Dr. Marc Gitzinger
E-mail: infoanti spam bot@bioversysanti spam bot.com
Tel: +41 61 633 22 50

“Our mission at Canyon Pharmaceuticals is to connect people and science to deliver life-saving medicines that serve today’s unmet needs,” notes Dawn Bell, PharmD, Senior Vice President and General Manager of Canyon’s US subsidiary.  “We worked closely with our acute-care physician and pharmacy colleagues to understand the gaps with current therapies and subsequently launched a highly differentiated anticoagulant that serves critical unmet needs in the hospitalized patient.”

“To achieve this recognition is truly gratifying and a testament to the important unmet needs in the anticoagulant marketplace that Iprivask is able to address,” says Seng Chin Mah, CEO of Canyon Pharmaceuticals Group AG.

About Canyon

Canyon PharmaceuticalsTM is a privately held specialty biopharmaceutical company focused on delivering innovative therapeutic solutions that target important cellular pathways in thrombosis, tumor growth, and metastasis. Canyon holds exclusive world-wide rights to desirudin, a subcutaneous (SC) recombinant direct thrombin inhibitor (DTI), and to pegmusirudin, a pegylated recombinant DTI with a longer duration of action than desirudin.

Media Contact:
Dr. Seng Chin Mah
E-mail: seng_chin.mahanti spam bot@canyonpharmaanti spam bot.com
Tel: +41 61 201 1383
http://www.canyonpharma.com/

In general, the collaboration between industry and science is strong. The authors of the report also highlighted the role of the authorities and institutions, which are among the most efficient and transparent in the world. They describe Switzerland’s infrastructure as “excellent”.

Flexible labor market
Switzerland can also thank the strong financial sector for its performance. The labor market is said to be very efficient - second only to that of the South-East Asian city of Singapore according to the WEF. The experts rate the business environment as one of the most stable of all.

For more information: www.weforum.ch